Skip to main content

A randomised, double-blind, placebo-controlled, parallel group trial evaluating safety, tolerability, pharmacodynamics and pharmacokinetics of BI 1291583 one tablet once daily over 12 weeks versus placebo in adult patients with cystic fibrosis bronchiectasis (ClairaflyTM)

Open
  • Protocol code: 1397-0013
  • EudraCT code: No aplica
  • Research group: Pneumology
  • Service: Pneumology
  • Principal investigator:  Álvarez Fernandez, Antonio
  • Pathology: Malalties del sistema respiratori
  • Phase: Fase II
  • Status: Recruiting volunteers